Key Releases are ad hoc announcements pursuant to SIX Swiss Exchange Article 53 Listing Rules.
Header
News Archive
Showing 1236 results
March 2021
-
Press Release
Novartis shareholders approve all resolutions proposed by the Board of Directors at the Annual General Meeting
Shareholders approve 24th consecutive dividend increase to CHF 3.00 (+1.7%) per share for 2020; representing a 3.8% yield1 and approximately 63% payout of free cash flowShareholders confirm Dr. Joerg… -
Press Release
Die Aktionäre von Novartis heissen an der Generalversammlung alle Anträge des Verwaltungsrats gut
Die Aktionäre bewilligen die 24. Dividendenerhöhung in Folge. Für 2020 wird die Dividende auf CHF 3.00 (+1,7%) je Aktie erhöht, was einer Rendite von 3,8%1 und einem Anteil des freien…
February 2021
-
Press Release
Novartis strengthens Oncology pipeline with successful closing of tislelizumab in-licensing
Adds tislelizumab, a uniquely designed anti-PD-1 monoclonal antibody for monotherapy and proprietary combination cancer therapies with Novartis portfolio and pipeline therapies Novartis will co-… -
Press Release
Novartis Cosentyx® gains EU label update for first-of-its-kind MAXIMISE data in axial manifestations of psoriatic arthritis
Cosentyx® (secukinumab) is the first biologic with proven efficacy in all 6 key manifestations of psoriatic arthritis (PsA), and the only biologic with fast and lasting relief of axial manifestations… -
Press Release
Novartis and the Bill & Melinda Gates Foundation collaborate to discover and develop an accessible in vivo gene therapy for sickle cell disease
Project brings together Novartis drug discovery and gene therapy expertise and funding support from the Gates Foundation Agreement aims to address disparity in access to treatments and to… -
Press Release
Novartis Entresto® granted expanded indication in chronic heart failure by FDA
Entresto is the first and only therapy approved in the US to treat patients diagnosed with guideline-defined heart failure to include both those with heart failure with reduced ejection fraction (… -
Ad-hoc Releases
Novartis Entresto® granted expanded indication in chronic heart failure by FDA
Entresto is the first and only therapy approved in the US to treat patients diagnosed with guideline-defined heart failure to include both those with heart failure with reduced ejection fraction (… -
Press Release
Novartis data show multiple sclerosis patients and nurses prefer Kesimpta® (ofatumumab) Sensoready® autoinjector pen
Multicenter survey results show MS patients and nurses prefer the Sensoready autoinjector pen for subcutaneous self-administration of Kesimpta over other autoinjectors for their current treatment (84… -
Press Release
Sandoz announces agreement to acquire GSK’s cephalosporin antibiotics business, reinforcing its leading global position in antibiotics
Sandoz to acquire three established brands sold in more than 100 marketsAcquisition, including leading global brand Zinnat®, confirms Sandoz commitment to antibiotics, following plans to expand its… -
Press Release
Novartis receives FDA Breakthrough Therapy designations for investigational STAMP inhibitor asciminib (ABL001) in chronic myeloid leukemia
Designation in patients with chronic myeloid leukemia (CML) resistant or intolerant to prior treatments based on positive data from pivotal Phase III ASCEMBL trial evaluating asciminib, an…
January 2021
-
Ad-hoc Releases
Novartis receives positive CHMP opinion for Kesimpta®* (ofatumumab), a self-administered treatment for adult patients with relapsing multiple sclerosis
Kesimpta is a targeted B-cell therapy that delivers superior efficacy with a similar safety and tolerability profile compared with teriflunomide, a first-line treatment in MS1CHMP opinion is… -
Press Release
Novartis signs initial agreement to provide manufacturing capacity for Pfizer-BioNTech COVID-19 vaccine
First of multiple agreements being explored by Novartis to leverage manufacturing capacity and capabilities to address pandemic, supporting global supply of COVID-19 vaccine Initial agreement signed…